Structure Therapeutics Inc.’s stock climbed 34.6% following a readout of what analysts call “competitive” and “exceptional” phase Ib data at 28 days of oral small-molecule glucagon-like peptide 1 (GLP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback